Minimum Effective Dose of Ropivacaine for Spinal Anesthesia for Cesarean Delivery

Minimum Effective Dose of Intrathecal Ropivacaine Required for Cesarean Delivery: A Prospective, Randomized Comparison Between L2-3 and L3-4 Approach

Ropivacaine is one of commonly used anesthetics for spinal anesthesia. Usually L2-3 or L3-4 intervertebral space is chosen for spinal anesthesia. The efficacy of ropivacaine injected into subarachnoid space depends on the given dose and the chosen intervertebral space. Appropriate dose could satisfy the requirement of operation and reduce incidence of the adverse reaction. But it is not certain about the minimum effective dose of ropivacaine in cesarean section through the two intervertebral spaces, respectively. This study is being conducted to find the minimum effective doses for L2-3 and L3-4 spinal anesthesia in cesarean section.

Study Overview

• Status: Completed
• Conditions: Spinal Anesthesia
• Intervention / Treatment: Procedure: Intervertebral space; Drug: Ropivacaine

Detailed Description

Some unexpected adverse reactions such as respiratory depression, vomiting, especially supine hypotensive syndrome could caused by a high dose of anesthetic in cesarean section. The investigators assumed that there be a minimum effective dose that will be associated with the best possible performance of ropivacaine for different intervertebral spaces(L2-3 and L3-4 in usual). That maybe enhance the comfort of parturient and safety of fetus.

This study is conducted as a prospective, randomized, up-down sequential dose of isobaric ropivacaine in 3 mL that will provide effective analgesia for 50% of parturients in cesarean section. The investigators use the combined spinal-epidural anesthesia(CSEA) technique in the study. The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group, and the testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group. If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.

The visual analogue scale (VAS) is used to rate the pain, where 0 is no pain and 10 is the worst pain imaginable. Criteria for evaluation:(1) effective: after spinal anesthesia finish, a dose that provide adequate sensory dermatomal anesthesia to pinprick to T6 or higher within 10 minutes, and the VAS is lower than or equal to 3 within 60minutes after skin incision; (2) ineffective: if the initial plane of sensory dermatomal anesthesia is lower than T6 or VAS is greater than 3 within 60 minutes after skin incision, the dose of ropivacaine is considered inadequate and additional lidocaine is given through epidural catheter.

Motor assessments are performed at the start of operation. Motor block in the lower limb is assessed by a modified Bromage scale (0=no paralysis, 1=unable to raise extended leg, 2=unable to flex knee,3=unable to flex ankle). All of the assessments are made by an anesthetist who is blinded to the group assignment as well as to the dose injected.

On the other hand, the investigators will compare the incidence of adverse reaction between the L2-3 and L3-4 group.

Using the Dixon and Massey up-and-down method study design, 60 patients scheduled for elective cesarean section will be included in the study, 30 for each group.

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 021
      • Shanghai Sixth People's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 35 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Full term parturient(> 37 and <42 weeks gestation)
• Above 20 years and below 35 years
• American Society of Anesthetists(ASA) I to II
• Singleton pregnancy
• Elective cesarean section
• Body weight during 60-85kg, height during 150-170cm

Exclusion Criteria:

• Patient refusal
• Hypertension
• Diabetes mellitus
• Heart diseases
• Asthma
• Abnormal fetus or placenta
• Contraindications to combined spinal-epidural anesthesia(CSEA)
• Allergy to ropivacaine

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: L2-3 intervertebral group; The initial dose of ropivacaine for subarachnoid is chosen as 12 mg in L2-3 intervertebral space group.	Procedure: Intervertebral space; Drug: Ropivacaine; The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.; Other Names: Naropin
EXPERIMENTAL: L3-4 intervertebral group; The initial dose of ropivacaine for subarachnoid is chosen as 15 mg in L3-4 group.	Procedure: Intervertebral space; Drug: Ropivacaine; The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.; Other Names: Naropin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
sensory block assessment evaluated with visual analogue scale (VAS) and sensory dermatomal anesthesia	Sensory block assessment will be evaluated with VAS and sensory dermatomal anesthesia. Criteria for evaluation of anesthetic efficacy:(1) effective: within 10 minutes after intrathecal injection, a dose that provides adequate sensory dermatomal anesthesia to pinprick to T6 or higher, and the VAS is lower than or equal to 3 within 60minutes after skin incision; (2) ineffective: the initial plane of sensory dermatomal anesthesia is lower than T6 or VAS is higher than 3 within 60 minutes after skin incision. VAS is a psychometric response scale which can be used in questionnaires. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end-points, where 0 was no pain and 10 was the worst. A dermatome is an area of skin that is mainly supplied by a single spinal nerve.Usually the upper sensory dermatomal anesthesia is used to assess the effect of intrathecal anesthesia.	during the entire procedure of operation

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
motor block accessment	Motor block in the lower limb will be assessed by a modified Bromage scale (0=no paralysis, 1=unable to raise extended leg, 2=unable to flex knee,3=unable to flex ankle) .	10minutes after the spinal anesthesia finished

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
incidence of adverse reaction	The investigators will compare the incidence of adverse reaction between the L2-3 and L3-4 group such as maternal hypotension, bradycardia, respiratory depression, nausea and vomiting.	during the entire procedure of operation
effect of abdominal muscle relaxation	The quality of abdominal muscle relaxation will be evaluated by the obstetrician as excellent (no disturbing muscle strain), satisfactory (disturbing, but acceptable) or unsatisfactory (unacceptable).	during the entire procedure of operation

Collaborators and Investigators

• Sponsor: Shanghai 6th People's Hospital

Study record dates

Study Major Dates

• Study Start (ACTUAL): September 30, 2015
• Primary Completion (ACTUAL): May 31, 2017
• Study Completion (ACTUAL): June 30, 2017

Study Registration Dates

• First Submitted: September 19, 2015
• First Submitted That Met QC Criteria: September 30, 2015
• First Posted (ESTIMATE): October 1, 2015

Study Record Updates

• Last Update Posted (ACTUAL): March 1, 2018
• Last Update Submitted That Met QC Criteria: February 28, 2018
• Last Verified: February 1, 2018

More Information

Terms related to this study

• Keywords: ropivacaine; cesarean delivery; intrathecal; dose-response relationship; minimum effective dose; intervertebral space
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Central Nervous System Depressants; Peripheral Nervous System Agents; Sensory System Agents; Anesthetics; Anesthetics, Local; Ropivacaine
• Other Study ID Numbers: 2015-35-(1)